A phase II placebo-controlled study to assess the efficacy and safety of KRP-KC318E in patients with accommodative asthenopia
Latest Information Update: 20 Dec 2021
At a glance
- Drugs KRP-KC318E (Primary) ; Cyanocobalamin
- Indications Eye disorders
- Focus Therapeutic Use
- Sponsors Senju Pharmaceutical
- 20 Dec 2021 New trial record